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ABSTRACT: The correlation between both prostate specific antigen levels (PSA) and 
prostate specific antigen density (PSAD) and age, prostate volume parameters, body mass 
index, and the International Prostate Symptom Score (IPSS) were studied in a community- 
based population. A sample of 502 men aged 55 through 74 years was evaluated, excluding 
those with a serum PSA above 10 ng/ml, those with biopsy proven prostate cancer, and 
those who had previously undergone a prostate operation. 
PSA and PSAD did not correlate with the body mass index. Weak correlations were found 
between PSA and age (r = 0.25; P < 0.001), PSAD and age (r = 0.17; P < 0.001) and between 
PSA and the total prostate volume (r = 0.58; P < 0.001). PSA did not correlate indepen- 
dently with age after adjustment for volume ( P  = 0.22). The finding that PSAD correlates 
with age (r = 0.17; P < 0.001) is partly explained by the incomplete volume adjustment of 
PSAD which is proved by the positive correlation between PSAD and prostate volume (r = 
0.26; P < 0.001). 
In the main target age-range for prostate cancer screening there is a poor basis for the use 
of age-specific reference values or volume adjustment for PSA levels in order to increase the 
clinical usefulness of this serum marker. Comparison of the results of the present study and 
studies conducted in others regions shows that there may be significant differences in PSA 
values per age stratum. Further studies are needed to clarify the reasons for these differ- 
ences. 0 1995 Wiley-Liss, Inc. 
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INTRODUCTION others [7,81 have not been able to find a clear rela- - -  
tionship between serum PSA levels and the amount 
of hyperplastic BPH tissue. In spite of the results of 
the latter studies, attempts have been made to in- 
crease the specificity of the PSA assay by prostate 
volume adjustment [9,10]. 
Prostate specific antigen (PSA) is a serine protease 
produced by the epithelial cells of the prostate [l]. 
The upper range of normal for the monoclonal pros- 
tate specific antigen level as recommended by the 
manufacturer is 4 ng/ml (Hybritech, San Diego, CA). 
However, it has been shown that benign prostatic 
hyperplasia (BPH) can be associated with elevated _ _  
prostate 'pecific antigen levels in 21-53'% Of the pa- 
that the Serum PSA level is elevated by O . 3 l O  0.25 
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Several studies have correlated serum PSA with 
age and with the total prostate gland volume, as mea- 
sured by transrectal ultrasound [lo-131 in men in 
whom prostate cancer has been excluded with a rea- 
sonable level of certainty. Two of these studies were 
done in a community-based population [12,13]. The 
men included in the study by Collins et al. [13] were, 
however, preselected on the basis of the presence of 
moderate to severe symptoms of prostatism and/or a 
flow rate below 15 ml/sec. The results of these studies 
were contradictory as to the aspect of association be- 
tween serum PSA levels and age. 
Kane et al. [lo] evaluated 1,695 men with no like- 
lihood of clinically significant prostate cancer be- 
tween the ages of 55-70 years. These men had no 
history of prostatic surgery. In this study, a relation- 
ship was observed between serum PSA and prostate 
gland volume but not between age and PSA levels or 
between symptoms of prostatism and PSA levels in- 
dependent of gland volume. 
Babaian et al. [11] studied 343 self-referred men 
and 65 physician-referred men because of an abnor- 
mal digital rectal examination or transrectal ultra- 
sound, or an elevated serum PSA. These men had a 
median age of 62 years (range 29-84 years). This 
study showed significant and independent associa- 
tions between prostate gland volume and PSA level 
and between age and PSA level. 
Oesterling et al. [12] studied 471 men, aged 40-79 
years, who were randomly selected from the commu- 
nity. In this study a relationship was found between 
PSA and both prostate volume and age. 
Collins et al. [13] reported data from a community- 
based population of 472 men aged 40-79 years in 
whom prostate cancer had been excluded. An inde- 
pendent relation between PSA and both age and 
prostate volume was observed in this study. 
The present evaluation was performed to further 
clarify the relationship between both PSA and prostate 
specific antigen density (PSAD) and age, prostate vol- 
ume, symptoms of prostatism and body mass index in 
a community-based population of men aged 55-74 
years who had no history of prostate surgery and in 
whom prostate cancer had been excluded with rea- 
sonable certainty. It was not the purpose of this study 
to evaluate the relative importance of PSA, digital 
rectal examination (DRE), and transrectal ultrasound 
(TRUS) in a prostate cancer screening program. 
MATERIALS AND METHODS 
Study Design 
The community-based data for this study were col- 
lected as part of a randomized pilot study of the value 
of screening versus no-screening for prostate cancer. 
TABLE 1. Frequency Distribution of Men in Four 
Consecutive Age-Groups Between 55-74 Years of Age" 
Age Total population (%) Participants (%) 
55 -59 25.8 20.9 
60 - 64 27.9 32.0 
65-69 25.6 26.1 
70 -74 20.7 21.0 
Total 100 100 
*In the general population at the time of creation of the database 
and in the population of participants at the time they were actually 
seen for the study. 
Based upon the population registry and after taking 
care of the appropriate legal regulations, the munic- 
ipal authorities of the City of Rotterdam created a 
database containing the information necessary to 
contact all men aged 55 through 74 years of age re- 
siding in four different districts of the city. After be- 
ing invited by mail, 1,186 men agreed to participate in 
the study. The response rates for the four five-year 
age-groups between 55 and 74 years, varied between 
33 and 36.3%, resulting in a community-based pop- 
ulation with a slight overrepresentation of men be- 
tween 60-64 years of age and a slight underrepresen- 
tation of men aged 55-59 years of age (Table I). Part 
of this effect is explained by aging of the original da- 
tabase between the time of its creation and the time 
that the men were actually evaluated. An enquiry 
among participants and non-participants, which was 
conducted at the end of this study by the department 
of epidemiology of the community health services of 
the City of Rotterdam, has shown that participants 
were not more symptomatic or less symptomatic than 
non-participants [14]. 
In all of these men, demographic and other data 
pertinent to the study, including International Pros- 
tate Symptom Score (IPSS) [15], were recorded. A 
serum PSA (ng/ml; Hybritech-assay) determination 
was used as a pre-screening tool. If the PSA value 
was above 10 ng/ml, a work-up was advised because 
of the high probability for prostate cancer [16] and the 
person was excluded from randomization. This was 
the case in 30 out of 1,186 men (i.e., 2.5% of the total 
study-population; 15 of these 30 men were subse- 
quently diagnosed with prostate cancer). 
The remaining men (N = 1,156) were randomized 
between a screening and a no-screening group. In the 
latter group, no further studies were done. The 554 
men assigned to the screening group were further 
examined by DRE and TRUS of the prostate. 
Height (H) and bodyweight (BW) were recorded 
and the body mass index was calculated according to 
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the formula: BW/H2 (kg/m2). An index of 20-25 kg/m2 
is considered to be normal; a value above 25 kg/m2 
indicates overweight. Those who were subsequently 
found to have prostatic cancer (N = lo), those who 
had undergone a prostate operation (N = 39), and 
the few men who refused the transrectal ultrasound 
examination (N = 3) were excluded from the present 
evaluation. 
A community-based population of 502 persons in 
whom prostate cancer had been excluded with rea- 
sonable certainty and who had not previously under- 
gone a prostate operation was thus established. 
Procedures 
Symptoms. The questionaire used is the AUA-7 
symptom index [17] which has been adopted by the 
World Health Organization (WHO) as the interna- 
tional prostate symptom score (IPSS) [15]. According 
to AUA scoring conventions, the men were grouped 
in three categories of symptom severity: those with 
minor symptoms (IPSS 0-7), those who were moder- 
ately (IPSS 8-19) and those who were severely (IPSS 
20-35) symptomatic [17]. 
Prostate evaluation. A 7 MHz Bruel and Kjaer 
multiplane sector scanning probe was used to mea- 
sure prostate volumes with the transrectal planimet- 
ric technique [MI. This involves measuring the sur- 
face area of transverse sections taken through the 
prostate at 5 mm intervals. The average of two sur- 
face areas multiplied by 5 mm gives the volume for 
each step, and the cumulative volume allows the total 
prostatic volume (cm3) to be derived. The same tech- 
nique was used to determine the volume of the cen- 
tral prostate. The reliability of this method in our 
hands was shown in a previous study of the intra- 
and inter-observer error of the planimetric technique 
[19]. The transrectal ultrasound image of the prostate 
does not correspond exactly to McNeal's description 
[20] of zones. In this study, the relatively hypoechoic 
central part of the prostate, including adenoma tissue 
if present, has been defined as the central part of the 
gland and should not be confused with McNeal's cen- 
tral zone. Its volume is referred to as VolC as opposed 
to VolT for total volume of the prostate and VolP 
(VolT-VolC) for volume of the peripheral part of the 
prostate. In 47 of the 502 subjects, VolC was not de- 
termined separately due to an aselect temporary de- 
viation from the protocol by one of the ultrasonogra- 
phers. 
The PSAD [9] was calculated by dividing the PSA 
value by the total prostate volume. 
If the findings on DRE and/or TRUS were abnor- 
mal, prostate biopsies were taken. In case of an ele- 
vated PSA level alone (i.e., 4 < PSA < 10 ng/ml) in 
combination with normal findings on digital rectal 
examination and transrectal ultrasound, a biopsy was 
not performed. Of the original 554 men included in 
the screening group, 51 (9.2%) had a PSA value be- 
tween 4 and 10 ng/ml. Prostate biopsies were per- 
formed in nine of these 51 men because of abnormal 
findings on DRE and/or TRUS. Prostate cancer was 
found in five of these nine men, resulting in a cancer 
detection rate of 9.8% in men with a PSA value be- 
tween 4 and 10 ng/ml. This is lower than the detec- 
tion rate of 17.7% as reported by Catalona et al. [16] 
who used a more liberal biopsy protocol. If a similar 
detection rate would have been applicable in our pop- 
ulation, this would have resulted in the diagnosis of 
prostate cancer in four additional men, implying that 
four additional men should have been excluded from 
the present evaluation. The impact of this number on 
a total of 502 men is negligible. 
Statistical Analysis 
Spearman correlation coefficients (r) were used to 
evaluate the relations between PSA or PSAD and age, 
IPSS, body mass index, and prostate volume param- 
eters. The Kruskal-Wallis test was used to compare 
the levels of PSA and PSAD between the three IPSS- 
groups. If this test indicated significant differences it 
was followed by Mann-Whitney's test for pairwise 
comparisons of the median levels. Multivariate anal- 
ysis was used to evaluate various factors simul- 
taneously. In this latter analysis, serum PSA and 
prostate volume parameters were analysed after log- 
arithmic transformation to reduce skewness of distri- 
butions. This transformation was also used in the cal- 
culation of the coefficients of determination (r2). The 
level of statistical significance was set at P = 0.05 
(two-tailed). 
RESULTS 
Figure 1 shows the cumulative frequency distribu- 
tion of the PSA values. Two features of this frequency 
distribution are noteworthy. Firstly, this distribution 
is skewed towards the higher PSA values. Secondly, 
a relatively high percentage of men has a PSA-value 
of 0.1 ng/ml (3%) or less (5%). Seven percent of the 
men had a PSA value between 4 and 10 ng/ml. 
Figure 2 shows the cumulative frequency distribu- 
tion of the PSAD values. Of the men studied, 95% 
had a PSAD below 0.117 and 97.5% below 0.145. The 
median PSAD value of the study population was 
0.033, whereas 30% of the men had a PSAD value 
above 0.050 and 7% above 0.100. 
Descriptive statistics of PSA and PSAD for the dif- 
ferent age strata are shown in Table 11. 
Total prostate volume is positively correlated with 
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Fig. I. Cumulative frequency distribution of serum PSA values in 
502 men without prostate cancer or a previous prostate operation. 
Men with a serum PSA level above 10 ng/ml had been excluded. 
age (r = 0.26; P < 0.001). The correlations between 
PSA and age, IPSS, body mass index, and prostate 
volume parameters and the correlations between 
PSAD and age, body mass index, and IPSS are sum- 
marized in Table 111. There is a weak but statistically 
significant correlation between PSA and age (r = 
0.25; P < 0.001). This is also reflected by the increase 
in mean PSA in advancing 5 year age-groups (Table 
11). An equally weak correlation is found between 
PSA and IPSS (r = 0.16; P < 0.001). 
PSA and PSAD did not correlate with the body 
mass index. The correlations between PSAD and age 
(r = 0.17; P < 0.001) and PSAD and IPSS (r = 0.09; P 
< 0.04) are both weak. There is a slight increase in 
mean PSAD in advancing 5 year age-groups (Table 
11). Calculation of the coefficient of determination 
shows that only 6% of the variation in PSA and 3% of 
the variation in PSAD, respectively, can be explained 
by the variation in age. 
PSA correlates moderately with VolT (r = 0.58; P 
< 0.001) and with VolC (r = 0.58; P < 0.001). The 
correlation between PSA and VolP (r = 0.33; P < 
0.001) is weaker. Figure 3 shows the scattergram of 
PSA values versus total prostate volume (VolT). 
Using multivariate analysis, it was found that each 
doubling of VolP, with constant VolC, leads to an 
average increase of 31% ( P  = 0.007) of PSA. Each 
doubling of VolC, with constant VolP, however leads 
to an average increase of PSA of 108% ( P  < 0.001). 
Adjusted for both volume parameters there was no 
longer any significant correlation between PSA and 
age ( P  = 0.22). 
Figures 4 and 5 show the cumulative frequency of 
serum PSA levels and PSAD, respectively, in 502 men 
without prostate cancer and PSA < 10 ng/ml by In- 
ternational Prostate Symptom Score subgroups. The 
men were grouped as those with no or minor com- 
100 
93 ....~..~........ 
Fig. 2. Cumulative frequency distribution of PSAD values in 502 
men without prostate cancer or a previous prostate operation. 
Men with a serum PSA level above 10 ng/ml had been excluded. 
plaints (IPSS 0-7; N = 318), those with moderate 
complaints (IPSS 8-19; N = 120), and those with se- 
vere complaints (IPSS 20-35; N = 30). This grouping 
by total International Prostate Symptom Scores re- 
sulted in significant differences ( P  = 0.002) in median 
PSA values, whereas the median PSAD did not sig- 
nificantly differ ( P  = 0.17) between IPSS-groups. Fur- 
ther analysis showed that the median PSA value in 
the group with no or minor complaints (1.1 ng/ml) 
differed significantly ( P  = 0.005) from the median 
value in the group with moderate complaints (1.3 ng/ 
ml) and also significantly ( P  = 0.02) from the median 
value in the group with severe complaints (1.8 ng/ 
ml). The median PSA values in the latter two groups 
did not differ significantly ( P  = 0.36) from each other. 
The group of men with severe complaints, however, 
only consists of 30 men. 
DISCUSSION 
The correlations between PSA level and the vol- 
ume of the central (r = 0.58) and peripheral part of 
the prostate (r = 0.33) that were found in this study, 
support the idea that more PSA is produced in the 
central (hyperplastic) than in the peripheral part of 
the prostate. These findings are also in agreement 
with the fact that elevated PSA levels can be found in 
men without prostate cancer but with an enlarged 
prostate due to BPH. 
The positive correlation between PSA and age may 
be due to the fact that prostate volume increases with 
age. Multivariate analysis indeed showed that age is 
not an independent factor after adjustment for vol- 
ume. This is at variance with the results of other stud- 
ies that found independent effects of age and volume 
Babaian et al. [ll] claimed an independent effect of 
[ 11-13]. 
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TABLE 11. Descriptive Statistics of PSA (ng/ml) and PSAD Values 
(ng/ml/cm') for Consecutive 5 Year Age-Groups of Men Without 
Prostate Cancer and Without Previous Prostate Operation* 
55-59 (124) 60-64 (162) 65-69 (132) 70-74 (84) 
PSA-value 
Mean 
Median 
Minimum 
Maximum 
SD 
PSAD-value 
Mean 
Median 
Minimum 
Maximum 
SD 
1.2 
0.8 
< 0.1 
7.9 
1.3 
0.035 
0.030 
0.002 
0.173 
0.030 
1.5 
1.0 
< 0.1 
7.3 
1.5 
0.041 
0.029 
0.001 
0.200 
0.034 
1.8 
1.4 
< 0.1 
8.4 
1.6 
0.046 
0.038 
0.002 
0.326 
0.042 
2.4 
1.7 
< 0.1 
10 
2.2 
0.055 
0.043 
0.001 
0.309 
0.053 
'Men with a PSA value above 10 ng/ml had been excluded. 
~ ~ ~~ ~ ~ ~ ~~~~~ 
TABLE 111. Spearman Correlation Coefficients (r) 
Between PSA or PSAD and Age, IPSS, Body Mass Index, 
and Between PSA and Prostate Volume Parameters in 
Men Aged 55-74 Years Without Prostate Cancer and 
Without Previous Prostate Operation* 
Parameters correlated r r2 P-value 
PSA 
Body mass index 
IPSS 
VolT 
VOlC 
VOlP 
Body mass index 
IPSS 
Age 
PSAD 
Age 
-0.01 
0.25 
0.16 
0.58 
0.58 
0.33 
-0.07 
0.17 
0.09 
0.00 0.89 
0.06 < 0.001 
0.03 < 0.001 
0.34 < 0.001 
0.34 < 0.001 
0.11 < 0.001 
0.00 0.10 
0.03 < 0.001 
0.01 0.04 
0 '"1 8 0 O :o / 
I / 
0 0  
0 
0 
0 
I 
I I I I I 
20 40 60 80 100 
VOLT(cm3)  
Fig. 3. Scattergram of PSA values (ng/ml) versus total prostate 
volume (VolT;crn3). Drawn line [log(PSA) = -2.61 + 
I .70.log(VolT); r2 = 0.30 P < 0.00 I ] corresponds t o  least squares 
regression line after logarithmic transformation of both axes. 
'Men with a PSA value above 10 ng/ml had been excluded. Coef- 
ficient of determination is indicated by r2. All correlations are sta- 
tistically significant except those involving the body mass index. 
age and volume with the significance of one not being 
dependent on the other. The fact that these authors 
studied men over a wider age range (29-84 years) 
may be an explanation for this finding. Oesterling et 
al. [12] found that the serum PSA level was correlated 
with both age (r = 0.43; P < 0.001) and prostate vol- 
ume (r = 0.55; P < 0.001) and proposed age-specific 
reference ranges for serum PSA. Their results indi- 
cated that 30% of the variation in PSA could be at- 
tributed to the variation in prostate volume, but that 
age accounted for an additional 5% (P < 0.001) of the 
variation in PSA. Their study population was 
younger, with about half of the 471 men below the 
age of 55 years, and consequently represented a 
wider age range (40-79) than the age range in our 
study population. 
Dalkin and associates [21] also determined age- 
specific reference ranges for men between 50 and 79 
years old. Compared to the values determined by 
Oesterling et al. [12], their reference values were 
higher for men 60-69 years old (5.4 as opposed to 4.5 
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Fig. 4. Cumulative frequency of serum PSA levels in 502 men 
without prostate cancer or a previous prostate operation by in- 
ternational prostate symptom score-groups. Scores are grouped as 
no or minor complaints (IPSS 0-7; N = 352), moderate complaints 
(IPSS 8-19; N = 120), and severe complaints (IPSS 20-35; N = 
30). Men with a serum PSA level above 10 ng/ml had been ex- 
cluded. 
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Fig. 5. Cumulative frequency of PSAD values in 502 men without 
prostate cancer or a previous prostate operation by International 
Prostate Symptom Score-groups. Scores are grouped as no or 
minor complaints (IPSS 0-7; N = 352), moderate complaints (IPSS 
8-19; N = IZO), and severe complaints (IPSS 20-35; N = 30). 
Men with a serum PSA level above I0  ng/ml had been excluded. 
ng/ml) and lower for men 70-79 years old (6.3 as 
opposed to 6.5 ng/ml). The men included in the eval- 
uation of Dalkin et al. did not represent a community- 
based population but were recruited by advertise- 
ments in newspapers. 
The percentages of men with a PSA > 4 ng/ml by 
age-group in the Olmsted county population [12] can 
be compared with these percentages in the present 
population, if the population of men included in the 
present study is adjusted by the secondary inclusion 
of half of the 15 men with a PSA > 10ng/ml but no 
prostate cancer: 5.1% of the men between 55-59 
years in the present population and 2% of the men 
between 50-59 in the Olmsted county population 
have a PSA > 4ng/ml. The difference is even larger 
between 60-69 years with 13% in Olmsted county as 
compared to 7.3% in the present series. The median 
prostate volumes for the men between 60-69 years in 
Olmsted county and Rotterdam are comparable (34.6 
and 33.2 cm3, respectively). It should be noted, how- 
ever, that prostate volumes were not determined in 
the men with a PSA > 10 ng/ml making it impossible 
to exactly adjust the median prostate volume, but the 
addition of half of the seven men without prostate 
cancer and a PSA > 10 ng/ml between 60-69 years is 
unlikely to change the difference between the median 
prostate volumes very much. Between 70-74 years 
we find a percentage of 15.8% as compared to 19% for 
the group of 70-79 years in Olmsted county. Since 
the biopsy protocol was more liberal in the Olmsted 
county population, these differences cannot be due to 
a different percentage of men excluded because of a 
diagnosis of prostate cancer; if a more liberal biopsy 
protocol had been employed in our study we would 
most probably have found some more cancers in the 
group of men with a PSA > 4ng/ml. This would have 
resulted in the exclusion of a few more men with a 
PSA > 4 ngiml from the population of 502, resulting 
in an even lower percentage of men with a PSA > 4 
ng/ml but without prostate cancer per age stratum. 
Collins et al. [13] found a significant and indepen- 
dent correlation between both PSA and age (r = 0.37; 
P < 0.001) and PSA and total prostate volume (r = 
0.56; P < 0.001) but concluded that ”because of the 
non-linearity of these interrelationships, PSA may be 
best employed using absolute cut-off levels.” Com- 
paring the mean PSA values of the Scottish popula- 
tion and the present population (after correction for 
the men with PSA > 10 ng/ml but without prostate 
cancer as described above) shows that there are again 
considerable differences by age-group: the mean PSA 
value between 60-69 years is 1.8 ng/ml in the present 
population as compared to 3.1 ng/ml in the Scottish 
study. The mean prostate volume in these two pop- 
ulation does not differ for the age-group between 
60-69 years (36 versus 36.5 cm3). 
Theoretically, the correlation between PSA and 
age could have been influenced by the exclusion of 
men with a PSA > 10 ng/ml but without prostate 
cancer. If all men would have been included, 15 of the 
30 men with a PSA > 10 ng/ml would have been 
randomized for screening and consequently half of 
these (i.e., about seven) would have been free of 
prostate cancer. Proportionately, one, two, one, and 
three men with a PSA > 10 ng/ml would have to be 
added to the four respective advancing 5 year age- 
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groups between 55-74 years. These numbers would 
have a negligible influence on the correlation be- 
tween PSA and age. 
The lack of an independent correlation between 
age and PSA indicates that there is a weak basis for 
the proposal of age-specific reference ranges in the 
population of men between 55-74 years. Another fac- 
tor that should be taken into account is the finding 
that comparative data from Rotterdam, Olmsted 
County, and Scotland seem to indicate differences in 
PSA values per age-group despite the use of the same 
method of serum PSA determination (Hybritech). 
These differences may be due to population sample 
biases. To fully understand the reasons for these dif- 
ferences a more detailed epidemiologic analysis 
would be necessary, including, for example, an anal- 
ysis of data on types of BPH, incidence of prostatitis, 
and instrumentation rates. Until such information is 
available, it is prudent to realize that reference ranges 
determined for one particular region or country may 
not necessarily be valid for another area. Further- 
more, the proposed age-specific reference ranges 
have not yet been tested in actual clinical practice. 
In the present study, it was found that only 6% of 
the variation in PSA can be attributed to the variation 
in age. However, 34% of the variation in PSA can be 
attributed to the variation in volume. 
The correlation coefficient between PSA and total 
prostate volume observed in the present study (r = 
0.58) is almost identical to the data presented by 
Oesterling et al. [12] (r = 0.55) and by Collins et al. 
[13] (r = 0.56). The correlation coefficients between 
PSA and age show considerable differences: r = 0.25 
in the present study and r = 0.37 and r = 0.43 in the 
studies reported by Collins et al. [13] and Oesterling 
et al. [12], respectively. The major difference between 
these studies is the age range of men included, which 
was 55-74 years in the present study and 40-79 years 
in both other studies. It would be interesting to study 
the correlation coefficient between age and PSA in 
both other samples of men after exclusion of those 
who are not between 55-74 years of age. This may be 
important because the main target age-range for pros- 
tate cancer screening does not include men between 
40-55 years of age unless a heriditary factor is sus- 
pected: only 2% of all prostate cancers in American 
white men occur in those 55 years or younger, 
whereas the heriditary form of prostate cancer ac- 
counts for 43% of the cases with an onset below 55 
years of age [22]. 
Based on the fact that there is a positive correlation 
between PSA values and volume, the idea of defining 
reference values for different volume classes or to ad- 
just PSA for volume has been introduced [9,10]. The 
correlation coefficient between PSA and total volume 
in the present study, however, is only moderate. Fur- 
thermore, only 34% of the variation in PSA is ex- 
plained by the variation in volume of the central part 
of the gland. These results do not support the use- 
fulness in clinical routine and screening programs of 
PSA reference values for different volume classes, 
even if the volumes of the central or peripheral part of 
the gland are considered specifically. 
Of the men in the present study, only 2% had a 
PSAD greater than 0.15, whereas 97.5% had a PSAD 
below 0.145. In their original article on PSAD, Benson 
et al. [9] found that none of their 20 BPH patients had 
a PSAD value above 0.117. In the present study, 95% 
of the men had a PSAD below 0.117. 
Interesting is the finding that although PSA does 
not correlate independently with age (i.e., after ad- 
justment for volume), PSAD still correlates (r = 0.17; 
P < 0.001) with age. Since prostate volume is also 
positively correlated with age (r = 0.26; P < 0.001), a 
possible explanation for this finding may be that 
PSAD provides an incomplete volume adjustment. 
Indeed, the correlation between PSAD and total pros- 
tate volume in this study amounts to r = 0.26 ( P  < 
0.001), which proves that PSAD does not provide a 
full volume adjustment. An alternative explanation 
for the correlation between PSAD and age, could be 
the possible influence with increasing age of other 
factors than volume, such as elements of prostatitis or 
infarction. If this were true, one could reason that 
men with prostatitis or infarction would possibly be 
more symptomatic and that, consequently, PSAD 
values might differ significantly between IPSS 
groups. This is, however, not the case. Statistical 
analysis shows that although median PSA values dif- 
fer significantly between IPSS groups ( P  = 0.002) 
there is no significant difference of median PSAD val- 
ues between IPSS groups ( P  = 0.17) (see Fig. 5). 
Other factors that frustrate prostate volume correc- 
tion of serum PSA levels are the findings recently 
reported by Mandell et al. [23]. They found marked 
variations in stromal to epithelial ratios in BPH pa- 
tients and an absence of correlation between PSAD 
and grams of epithelium, and stromal to epithelial 
ratio. They also found an age dependent decrease in 
PSA production per gram of epithelium. 
SUMMARY 
1. Prostate volume adjustment with the intention 
to increase the specificity of serum PSA values in the 
detection of prostate cancer has been proposed either 
with specific volume ranges or with the use of PSAD. 
The moderate correlations between PSA and prostate 
volume parameters and the incomplete volume ad- 
justment that is provided by the use of PSAD, do not 
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support  the clinical usefulness of PSA reference val- 
ues for different volume classes, even if the volumes 
of the central or  peripheral part of the gland are con- 
sidered specifically. 
2. Age specific reference ranges for serum PSA val- 
ues have been proposed for use in screening for pros- 
tate cancer. The lack of an  independent correlation 
between age and PSA in  the present study does not 
support the clinical usefulness of this approach in 
men between 55-74 years old. 
3.  There may be significant regional differences in  
PSA values per age-group. Further studies are 
needed to clarify the reasons for these differences. 
4. The positive correlation between PSAD and age 
can be explained in part by the incomplete volume 
adjustment of PSAD. A n  increase with age of pros- 
tatic abnormalities such as prostatitis or infarctions, 
could be a n  alternative explanation. The present 
study does not support this latter possibility since 
there is no significant difference in PSAD between 
groups of men with different levels of symptom se- 
verity. 
5. There is no correlation between PSA or PSAD 
and body mass index. 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
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